Trader consensus currently assigns a 77% implied probability against any new COVID variant of concern before 2027, reflecting the absence of rapid emergence of highly divergent strains meeting WHO criteria for elevated public health risk. SARS-CoV-2 continues evolving primarily within JN.1-descendant lineages such as XFG, which dominates globally and prompted recent FDA advisory approval of updated monovalent vaccines targeting it for the 2026-2027 season. Closely monitored variants under surveillance, including BA.3.2 and NB.1.8.1 sublineages, show immune-escape potential yet remain at low clinical prevalence below 1% in sequencing data, with stable or declining shares amid low overall transmission. Wastewater and traveler surveillance have not signaled accelerated spread or compensatory mutations that would drive dominance before year-end. This environment supports expectations that existing genomic monitoring and vaccine adaptation will contain risks in the near term, though further mutations could still alter trajectories.